T
Thierry Folliguet
Researcher at University of Paris
Publications - 201
Citations - 9055
Thierry Folliguet is an academic researcher from University of Paris. The author has contributed to research in topics: Aortic valve replacement & Aortic valve. The author has an hindex of 37, co-authored 181 publications receiving 6169 citations. Previous affiliations of Thierry Folliguet include Paris 12 Val de Marne University & University of Lorraine.
Papers
More filters
Journal ArticleDOI
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
Jean-Philippe Collet,Holger Thiele,Emanuele Barbato,Olivier Barthelemy,Johann Bauersachs,Deepak L. Bhatt,Paul Dendale,Maria Dorobantu,Thor Edvardsen,Thierry Folliguet,Chris P Gale,Martine Gilard,Alexander Jobs,Peter Jüni,Ekaterini Lambrinou,Basil S. Lewis,Julinda Mehilli,Emanuele Meliga,Béla Merkely,Christian Mueller,Marco Roffi,Frans H. Rutten,Dirk Sibbing,George C.M. Siontis +23 more
TL;DR: A correction has been published: European Heart Journal, ehaa895, https://doi.org/10.1093/eurheartj/ehaa-895.
Journal ArticleDOI
Guidelines on myocardial revascularization.
Philippe Kolh,William Wijns,Nicolas Danchin,Carlo Di Mario,Volkmar Falk,Thierry Folliguet,Scot Garg,Kurt Huber,Stefan James,Juhani Knuuti,Jose Lopez-Sendon,Jean Marco,Lorenzo Menicanti,Miodrag Ostojic,Massimo F. Piepoli,Charles Pirlet,José L. Pomar,Nicolaus Reifart,Flavio Ribichini,Martin J. Schalij,Paul Sergeant,Patrick W. Serruys,Sigmund Silber,Miguel Sousa Uva,David P. Taggart +24 more
TL;DR: Guidelines and Expert Consensus Documents summarize and evaluate all available evidence with the aim of assisting physicians in selecting the best management strategy for an individual patient suffering from a given condition, taking into account the impact on outcome and the risk benefit ratio of diagnostic or therapeutic means.
Journal ArticleDOI
Myocardial cell death in fibrillating and dilated human right atria.
Christine Aimé-Sempé,Thierry Folliguet,Catherine Rucker-Martin,Maryla Krajewska,Stanislaw Krajewski,Michèle Heimburger,Michel Aubier,Jean-Jacques Mercadier,John C. Reed,Stéphane N. Hatem +9 more
TL;DR: In fibrillating and dilated atria, apoptotic death of myocytes with myolysis contributes to cellular remodeling, which may not be entirely reversible.
Journal ArticleDOI
Temporal Trends in Transcatheter Aortic Valve Replacement in France: FRANCE 2 to FRANCE TAVI
Vincent Auffret,Thierry Lefèvre,Eric Van Belle,Hélène Eltchaninoff,Bernard Iung,René Koning,Pascal Motreff,Pascal Leprince,Jean Philippe Verhoye,Thibaut Manigold,Géraud Souteyrand,Dominique Boulmier,Patrick Joly,Frédéric Pinaud,Dominique Himbert,Jean-Philippe Collet,Gilles Rioufol,Said Ghostine,Olivier Bar,Alain Dibie,Didier Champagnac,Lionel Leroux,Frederic Collet,Emmanuel Teiger,Olivier Darremont,Thierry Folliguet,Florence Leclercq,Thibault Lhermusier,Patrick Olhmann,Bruno Huret,Luc Lorgis,Laurent Drogoul,Bernard Bertrand,Christian Spaulding,L Quilliet,Thomas Cuisset,Maxence Delomez,Farzin Beygui,Jean-Philippe Claudel,Alain Hepp,Arnaud Jégou,Antoine Gommeaux,Anfani Mirode,Luc Christiaens,Charles Christophe,Claude Cassat,Damien Metz,Lionel Mangin,Karl Isaaz,Laurent Jacquemin,Philippe Guyon,Christophe Pouillot,Serge Makowski,Vincent Bataille,Josep Rodés-Cabau,Martine Gilard,Hervé Le Breton +56 more
TL;DR: The FRANCE TAVI registry provided reassuring data regarding trends in TAVR performance in an all-comers population on a national scale, and concerns remain regarding potentially life-threatening complications and pacemaker implantation.
Journal ArticleDOI
Minimally invasive versus conventional open mitral valve surgery: a meta-analysis and systematic review.
Davy Cheng,Janet Martin,Janet Martin,Avtar Lal,Anno Diegeler,Thierry Folliguet,L. Wiley Nifong,Patrick Perier,Ehud Raanani,J. Michael Smith,Joerg Seeburger,Volkmar Falk +11 more
TL;DR: Current evidence suggests that mini-MVS maybe associated with decreased bleeding, blood product transfusion, atrial fibrillation, sternal wound infection, scar dissatisfaction, ventilation time, intensive care unit stay, hospital length of stay, and reduced time to return to normal activity, without detected adverse impact on long-term need for valvular reintervention and survival beyond 1 year.